- Altamira Therapeutics ( NASDAQ: CYTO ) is trading 26% down after the company said its therapy, Bentrio, to treat acute COVID-19, did not meet main goal in a trial.
- Top line data from the trial, dubbed Covamid, showed trend for more pronounced reduction in nasal viral load and symptoms than no treatment, but primary endpoint was not met during the trial.
- In a separate trial, dubbed Nasar, an interim analysis based on the accumulated data from the first 53 participants showed a statistically significant reduction of nasal symptoms with Bentrio vs. saline nasal spray comparator.
- The Nasar main trial phase has been completed and full read-out is expected in Q2.
- The Covamid trial enrolled patients in Bulgaria and North Macedonia and randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, modified Bentrio or no treatment, followed by a 10-day observation phase.
For further details see:
Altamira falls 26% after acute COVID-19 therapy fails to meet main goal in trial